Northwest Biotherapeutics (NWBO) Operating Income: 2010-2025
Historic Operating Income for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$14.3 million.
- Northwest Biotherapeutics' Operating Income rose 3.25% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 2.78%. This contributed to the annual value of -$66.5 million for FY2024, which is 19.82% down from last year.
- Per Northwest Biotherapeutics' latest filing, its Operating Income stood at -$14.3 million for Q3 2025, which was up 3.11% from -$14.8 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Operating Income registered a high of -$10.0 million during Q3 2021, and its lowest value of -$21.1 million during Q2 2022.
- In the last 3 years, Northwest Biotherapeutics' Operating Income had a median value of -$14.8 million in 2024 and averaged -$15.3 million.
- The largest annual percentage gain for Northwest Biotherapeutics' Operating Income in the last 5 years was 79.01% (2021), contrasted with its biggest fall of 149.84% (2021).
- Northwest Biotherapeutics' Operating Income (Quarterly) stood at -$10.7 million in 2021, then tumbled by 70.27% to -$18.2 million in 2022, then rose by 16.70% to -$15.1 million in 2023, then dropped by 22.17% to -$18.5 million in 2024, then grew by 3.25% to -$14.3 million in 2025.
- Its Operating Income was -$14.3 million in Q3 2025, compared to -$14.8 million in Q2 2025 and -$17.3 million in Q1 2025.